The T cell response to a mixture of eight peptides derived from sequences of the Mycobacterium tuberculosis has been studied. The peptides were selected on the basis of complementary binding to nine HLA-DR molecules (HLA-DR1 to DR9). MTBmix-8 at 6 . 25 and 50 ¹ g/ml gave rise to significant stimulation (P < 0 . 05) of peripheral blood mononuclear cells (PBMC) from healthy tuberculin-positive and both untreated and treated diseased subjects, but not in any of a control group of healthy tuberculin-negative subjects. MTB-mix-8 stimulated proliferation of PBMC from healthy tuberculin-positive individuals at lower concentrations than the individual component peptides. However, the maximal stimulation achieved was only slightly higher than that achieved with individual peptides. MTBmix-8 also stimulated the production of interferon-gamma (IFN-°) in vitro. Using the mean 6 2 s.d. of the values for IFN-°production in the tuberculin-negative population as a cut-off, MTBmix-8 at 6 . 25 ¹ g/ml was able to detect infection with a sensitivity of 100% in untreated patients, 87% in treated patients, and 82% in tuberculin-positive controls. The corresponding figures for the most potent single peptide (16p91-110) were: 66% in untreated patients, 71% in treated patients and only 42% in controls. Thus, using the IFN-°-based assay, which has the additional advantages of speed and does not require radioactivity, the mixture of peptides is more sensitive than single peptides in diagnosing infection.
INTRODUCTION
Infection by Mycobacterium tuberculosis is of increased public health concern following recent moderate increases in the number of cases in developed countries [1] . The method for detection of infection is the skin reaction to purified protein derivative (PPD) of M. tuberculosis. Although attempts have been made to define species-specific PPD reagents, the test remains compromised in both specificity and sensitivity [2] . One of the reasons for the lack of specificity is sensitization by environmental mycobacteria [3] . This is particularly relevant in low prevalence countries which do not routinely administer bacille Calmette-Guérin (BCG) vaccination and in which control therefore is based upon the detection of infected cases and chemoprophylaxis. False-positive results may lead not only to inappropriate chemoprophylaxis but also to an overestimate of the incidence of tuberculosis within the community. In addition, there are operational problems with PPD because of its poorly defined content, batch to batch variation, difficulty in standardization, dosage and administration.
Many of the antigenic constituents of mycobacteria are shared between human pathogens and environmental, non-pathogenic organisms. The search for alternatives to PPD has been mainly at the level of species-specific antigens. There are several candidate antigens, but none has yet been subjected to clinical trial [4] [5] [6] . An alternative to proteins would be to use peptides, which have the practical advantage of low cost. In addition, if an antigen common to more than one mycobacterial species is selected, peptides of species-specific sequence can be chosen. Consequently, if the antigen is of compromised specificity (such as the 19 kD [7] ) it is possible to select epitopes from regions of the genome which are M. tuberculosis-specific. In this study we have used epitopes of the 16-, 19-and 38-kD molecules of M. tuberculosis [8] [9] [10] .
The major obstacle in the use of peptides, MHC restriction, is in part offset by genetically permissive recognition of the immunodominant epitopes [11] [12] [13] . However, immunodominant epitopes are selectively rather than universally permissive, as they often fail to bind certain alleles (Jurcevic et al., submitted for publication). An additional problem is presented by the low precursor frequency of T cells recognizing any single epitope (approx. 1 in 100 000). The practical consequence is that the magnitude of the in vitro response is usually considerably lower to a single epitope than to a whole organism or to PPD.
The aim of this study was to explore if mixing of a limited number of M. tuberculosis-specific and genetically permissive immunodominant epitopes would constitute a T cell reagent of amplified test sensitivity, matching that of PPD. For this purpose, we selected eight M. tuberculosis peptides (MTBmix-8) on the basis of their complementary binding to a wide range of HLA-DR molecules. As MTBmix-8 contains at least one peptide which binds to each of the major HLA-DR alleles, we expected that such a mixture could achieve broad T cell recognition and hence increase the test sensitivity for human populations. Furthermore, we assumed that an individual should ideally recognize several epitopes from the MTBmix-8 which would lead to an overall increase in stimulatory capacity and amplified T cell proliferation and interferon-gamma (IFN-) responses.
SUBJECTS AND METHODS

Subjects
Patients were recruited from the Department of Infection and Tropical Medicine (Northwick Park Hospital, Harrow, UK). On anonymous testing, none was positive by ELISA for HIV-1 (R. Wall, personal communication). Proliferative responses and/or IFN-production of peripheral blood mononuclear cells (PBMC) were studied in 16 untreated patients (UP; 12 male, four female, average age 29 . 2 years), 20 patients during treatment (TP; 12 male, eight female, average age 38 . 0 years), 17 PPD + controls (10 male, seven female, average age 37 . 1 years) and six PPD -controls (one male, five female, average age 26 . 5 years). Of the UP, 12 had pulmonary tuberculosis, of whom 11 were sputum-positive. The remaining four patients had lymphadenopathic (n = 2), mesenteric, and musculoskeletal disease. Thirteen of the treated patients had pulmonary tuberculosis, three lymphadenopathy, and one each of miliary, genitourinary, osteomyelitis, and musculoskeletal disease. Ethical approval for this study was given by the Harrow Local Research Ethical Committee, EC1646. PPD + healthy controls who had received BCG vaccination were recruited from laboratory and clinical colleagues. Most were of low occupational exposure to tuberculosis. PPD positivity was defined as a skin reaction of > 5 mm induration to one tuberculin unit. PPD -healthy controls, who had not received BCG vaccine, were recruited from the psychiatric nursing staff at the Maasziekenhuis (Boxmeer, The Netherlands).
Synthetic peptides
Peptides were made using solid-phase/Fmoc chemistry. Sequence integrity was verified by mass spectrometry and homogeneity by reverse-phase high-performance liquid chromatography (HPLC). Peptide purity was > 85%. N-terminally biotinylated peptides were made by shaking the fully side-chain-protected peptide resin in a solution of 1 . 5 equivalents of both biotinamidocaproate-N-hydroxysuccinimide ester and diisopropylethylamine in dimethyl sulphoxide (50 ml per mmol) for 2 h; cleavage, deprotection and work up were then carried out in the usual manner. Peptide sequences are shown in Table 1 . The sequence of the HA/306-18 peptide is APKYVKQNTLKLAT (an N-terminal alanine was added to the original sequence so as to facilitate biotinylation); the CLIP peptide (human invariant chain 104-119) sequence is VSKMRMATPLLMQALP. Biotinylated HA/306-18 ( bio HA/306-18) and CLIP were used as references in binding competition assays.
Polyalanine substituted peptides were variants of the 38p350-369 peptide, sequences: AAAFQPAAAAAAKAA; AAAFQPLAAAA-AKAA and AAAFQPAAAAVAKAA.
Purification of HLA-DR molecules
HLA-DR molecules were purified essentially as described before [14, 15] . Briefly, Epstein-Barr virus (EBV)-transformed HLA-DR homozygous lymphoblastoid B cell lines (LBL), HOM-2, MGAR, VAVY, BOLETH, SWEIG, AMALA, MOU, MADURA and DKB, were lysed at 10 8 cells/ml in PBS containing 1% NP-40, 0 . 5 mM PMSF and 0 . 05% NaN 3 for 2 h at 48C. Cell debris was removed by centrifugation at 10 000 g for 1 h. HLA-DR molecules were isolated from the lysates by recirculating (0 . 5 ml/min) through a 5 ml column of Protein-A/Sepharose CL-4B covalently coupled to the L-243 MoAb (anti-MHC). The column was then washed with 50 ml of PBS + 10 mM n-octyl -D-glucopyranoside (OG) and the HLA-DR protein eluted from the column at pH 11 . 5 (0 . 15 M NaCl, 0 . 05 M NaHCO 3 , 10 mM OG): 1 . 0 ml fractions were collected directly into 0 . 25 ml of 1 M NaH 2 PO 4 pH 6 . 8. The protein-containing fractions were pooled and concentrated using Centriprep-30 ultra-filtration membranes (Amicon Inc., Beverly, MA). The final protein concentration was determined using a Microtitre BCA assay (Pierce Chemical Co., Rockford, IL).
MHC-peptide binding assay
MHC-peptide binding was tested using purified HLA-DR molecules [14] . Briefly, HLA-DR molecules (0 . After 48 h incubation at room temperature, the MHC-peptide complexes were diluted with 100 l of blocking buffer (5% non-fat dry milk/PBS, 0 . 1% Tween-20), divided into triplicate sets and transferred to previously prepared microtitre plates coated overnight with L-243 MoAb (at 1 g/well). After 2 h incubation with shaking at 48C, plates were washed six times with PBS/0 . 1% Tween-20 and the quantity of bound biotinylated peptide was determined colorimetrically using Streptavidin-peroxidase and tetramethyl benzidine (Sigma Chemical Co., Poole, UK). Absorbances in the presence of the reference peptide, without added competitor, were in the range 0 . 2-0 . 5, while the background absorbances were < 0 . 02. Statistical analyses were performed using Student's t-test at the level of P < 0 . 05.
Lymphocyte proliferation test
Whole citrated blood was diluted 1:2 and PBMC were separated on a Ficoll gradient (Pharmacia, Uppsala, Sweden). The cells were then washed twice in PBS and plated in triplicate wells at 1 . 5
5 /well in the presence of 5% AB + human serum in 96 U-well plates (Nunc, Roskilde, Denmark) for 6 days. DNA synthesis was assayed by 3 H-thymidine incorporation (Amersham, Aylesbury, UK). PBMC (5   2   10 6 /ml) were cultured for 48 h in the presence of antigen and 5% AB + human serum. Supernatants were harvested and stored at -708C until use. Maxisorp (Nunc) plates were coated with 50 l/well of murine anti-IFN-MoAb 1-DIK at 2 . 5 g/ml (Mabtech AB, Stockholm, Sweden). The plate was blocked for 1 h at room temperature in PBS/0 . 05% Tween/3% w/v bovine serum albumin. Each plate was calibrated against a standard preparation of cytokine (Genzyme, Cambridge, MA). The plates were incubated with 100 l sample/well in duplicate for 4 h and then washed four times. The plates were incubated at room temperature for 1 h in 100 l biotinylated detection antibody MoAb 7B-61 anti-IFNat 1 g/ml (Mabtech) and then washed five times. Streptavidinperoxidase (100 l; 1 g/ml) was added to each well and incubated for 45 min. Six final washes were followed by 150 l K-Blue substrate (ELISA Technologies, Lexington, KY) followed by KRed stop solution (50 l) when colour development was optimal.
Induction and assay of IFN-
RESULTS
Binding of MTB peptides to HLA-DR molecules
Eight peptides derived from the sequences of the 16-, 19-and 38-kD antigens were tested for binding to several purified HLA-DR molecules. The binding affinities to HLA-DR1 varied considerably ( Fig. 1) : strong binding (IC 50 < 10 M) was obtained for 38p1-20, 38p350-369 and 16p91-110, whereas 38p270-289 and 16p111-130 bound with moderate affinity (IC 50 = 10-100 M). Low-affinity binding was shown by the peptide 16p21-40, whereas peptides 19p11-30 and 38p305-324 failed to bind to DR1 at concentrations used in this assay. Influenza haemagglutinin peptide (HA/306-18) was used as the high-affinity binding reference peptide for DR1.
The peptides had variable binding to nine HLA-DR alleles (Table 1) . Some peptides (e.g. 16p91-110 and 38p350-369) bound several HLA-DR alleles with high affinity, although both failed to bind HLA-DR3. High-affinity binding to DR3 was found only for the 38p270-289 peptide. We concluded that a combination of peptides with complementary binding to HLA-DR molecules could provide a mixture containing at least one high-affinity peptide for each DR allele. On this principle we selected peptides (MTBmix-8) for analysis of lymphocyte stimulatory capacities (Table 1) .
T cell proliferation
The lymphocyte stimulatory capacity of individual peptides and combinations of two to eight peptides was studied. In a representative experiment (Fig. 2a) , the most stimulatory peptides for PBMC of a healthy PPD + subject were 16p111-130, 38p305-324, 16p91-110 and 38p270-289. As presented in Fig. 2b , increasing the number of peptides in an arbitrary combination increased the proliferation, but this increase was not linear and stimulation was lower than the sum of the responses to individual peptides. As the mixture containing all eight peptides was the most stimulatory, it was adopted for the subsequent evaluation in larger groups.
A dose-response evaluation of MTBmix-8 showed that the peptide mixture was stimulatory at lower doses than individual peptides 38p350-369 and 16p91-110 (Fig. 3) . However, the plateau of stimulation achieved with MTBmix-8 was slightly higher than stimulation achieved with individual peptides. A mixture of peptides with multiple alanine substitutions, PolyAlaMix, failed to stimulate PBMC. Similar results were obtained with PBMC from five other HS controls.
By comparison with unstimulated cells, all four preparations (16p91-110 peptide, MTBmix-8 at 6 . 25 and 50 g/ml and PPD) caused significant stimulation (P < 0 . 05 in all cases) in untreated patients, treated patients, and PPD + controls (Fig. 4) . PPD was more potent a stimulus than any peptide or peptide mix in all infected groups (P < 0 . 05 in all cases). The mean value of 3 Hthymidine incorporation in the presence of MTBmix-8 was higher than in the presence of its constituent, 16.10 peptide, in all groups except PPD -subjects, although the difference did not reach statistical significance. The data obtained with 16p91-110 are representative of other single peptide constituents of MTBmix-8.
IFN-production
A subset of the same subjects (10 UP, 16 TP, eight PPD + and five PPD -controls) was studied for IFN-production in ex vivo stimulated cells (Fig. 5) . In all three sensitized groups there was significantly raised IFN-production in response to the MTBmix-8, peptide 16p91-110 and to PPD (P < 0 . 05) compared with medium alone. Amongst the non-sensitized controls there was no significant stimulation by any preparation. Using the mean + 2 s.d. of the values for the non-sensitized population as a cut-off, MTBmix-8 at 50 g/ml was able to detect infection with a sensitivity of 89% in UP, 87% in TP, and 82% in PPD + controls. The corresponding figures for MTBmix-8 at 6 . 25 g/ml were 100%, 87% and 82%, respectively; and for PPD 100% in all sensitized groups. The single peptide 16p91-110 was able to detect infection in 66% of UP, 71% of TP, and only 42% of PPD + controls. Thus, by contrast with the cell proliferative assays, in the IFN--based assay the mixture of peptides is more sensitive than single peptides in diagnosing infection.
T cell responses to a mixture of immunogenic peptides
DISCUSSION
Although peptides are widely acknowledged for their potential in diagnosis and subunit vaccines [16] , there have so far been very few practical applications, mainly due to the extensive polymorphism within the human MHC. Recently acquired knowledge of the MHC-peptide interaction suggests that many peptides bind permissively to several MHC molecules. However, no peptide binds universally [17] . This limitation can be overcome, as demonstrated here, by combining several peptides to complement each other in binding to a wide spectrum of human HLA alleles.
The mixture of peptides (MTBmix-8) used in this study was selected on the basis of screening of a larger set of 49 peptides derived from sequences of the 16-, 19-and 38-kD antigens for binding to HLA-DR molecules. A number of the peptides with high binding affinity to HLA-DR have been shown to cause T cell stimulation [11] [12] [13] , indicating that binding to MHC and immunodominance are related. In the pilot experiments (Fig. 2b ) the mixture containing eight peptides was most stimulatory and therefore adopted for the remainder of the evaluation. It is possible that further empirical testing and MHC binding data could lead to a 'better' mix.
MTBmix-8 proved to be stimulatory in most infected or sensitized individuals and showed less individual variations than single peptides, especially in the IFN--based assay (Fig. 5) . Furthermore, MTBmix-8 was stimulatory at lower concentrations than single peptides: optimal concentrations for most of the single peptides were 50 g/ml, and for MTBmix-8 it seems they were around 6 . 25 g/ml of each peptide. MTBmix-8 was more efficient in stimulating the production of IFN-than single peptides (sensitivity of 100% in UP, 87% in TP, and 82% in PPD + controls). The broader recognition of MTBmix-8 in this assay could be explained by the fact that HLA-DR is a relative restricting element, despite permissive recognition, and that by selection of at least one peptide binding to each of the major HLA-DR types, we have overcome this obstacle.
Antigen- [18] and epitope-specific [12] anergy has been previously documented in patients with tuberculosis. When the healthy tuberculin-positive (10 321 6 3650 ct/min) and untreated groups (3834 6 1411 ct/min) were compared, such an effect was seen with the higher dose of MTBmix-8 (P < 0 . 01); the same trend was seen with peptide 16p91-110, though the difference did not reach significance. Interestingly, anergy was not seen with the lowdose MTBmix-8 or PPD (Fig. 4) . During treatment, these differences between peptide preparations tended to disappear, resulting in similar geometric mean ct/min in this group (Fig. 4) .
Contrary to our expectations, combined peptides failed to act synergistically, or even additively, and the stimulatory capacity of MTBmix-8 was slightly higher than that of the best, single peptide (16p91-110). The absolute level of IFN-produced in presence of MTBmix-8 was almost invariably less than that induced by PPD. Even though several peptides from MTBmix-8 are presumably recognized by each individual, the sensitivity may still be limited by the number of epitope-specific T cells. Alternatively, this could be due to competition between peptides for a limited number of binding sites (HLA-DR molecules) on the surfaces of antigenpresenting cells (APC). Consequently, increases in either the number or concentration of peptides could lead to a decrease in the level of HLA-binding by any single peptide. This explanation is supported by the observation that MTBmix-8 in some cases had a declining stimulatory capacity at high concentrations. Thus, the peptide mixture increased the number of responders rather than their individual levels of proliferation or IFNproduction.
Synthetic peptides are neither taken up into nor processed by APC [19] and bind to a relatively small proportion (< 10%) of MHC class II molecules on the cell surface [20] . Hence, administration of peptides in the form of multi-antigenic peptides (MAP), microspheres or liposomes could enable APC to take up the peptides and make them more readily available for loading of newly synthesized MHC molecules. In this way, competition with bound endogenous peptides could be reduced. It will be relevant to explore whether peptide modification or their incorporation into MAPs, microspheres or liposomes could improve their T cellstimulatory capacity. g , medium alone.
